| 1 |
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al. · JAMA
Open access114 authors |
6 Apr 2020 |
5,912 |
| 2 |
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al. · The Lancet
Open access |
2 Oct 2013 |
2,223 |
| 3 |
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fátima Cardoso et al. · New England Journal of Medicine
Open access |
24 Aug 2016 |
2,097 |
| 4 |
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
Giacomo Grasselli et al. · JAMA Internal Medicine
Open access149 authors |
15 Jul 2020 |
1,747 |
| 5 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology
Open access |
31 Aug 2015 |
1,111 |
| 6 |
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine
Open access |
22 Oct 2014 |
1,097 |
| 7 |
Comparison between different D ‐ D imer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study
Gualtiero Palareti, Cristina Legnani, Benilde Cosmi et al. · International Journal of Laboratory Hematology
Open access |
12 Sep 2015 |
910 |
| 8 |
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients
Evelina Tacconelli, Maria Adriana Cataldo, Stephanie J. Dancer et al. · Clinical Microbiology and Infection
Open access |
12 Dec 2013 |
887 |
| 9 |
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
François‐Clément Bidard et al. · The Lancet Oncology
|
11 Mar 2014 |
848 |
| 10 |
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al. · The Lancet
Open access |
May 2020 |
799 |
| 11 |
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
Fausto Petrelli, Gianluca Tomasello, Karen Borgonovo et al. · JAMA Oncology
|
27 Oct 2016 |
758 |
| 12 |
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
Carlo Salvarani et al. · JAMA Internal Medicine
Open access |
20 Oct 2020 |
733 |
| 13 |
Acute pulmonary embolism and COVID-19 pneumonia: a random association?
Gian Battista Danzi, Marco Loffi, Gianluca Galeazzi et al. · European Heart Journal
Open access |
25 Mar 2020 |
669 |
| 14 |
Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy
Enrico Baldi, Giuseppe Maria Sechi, Claudio Mare et al. · New England Journal of Medicine
Open access |
29 Apr 2020 |
668 |
| 15 |
Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study
Luigi Naldi et al. · Journal of Investigative Dermatology
Open access |
27 Jun 2005 |
645 |
| 16 |
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
Vittorio Pengo, Amelia Ruffatti, Cristina Legnani et al. · Journal of Thrombosis and Haemostasis
Open access |
30 Oct 2009 |
632 |
| 17 |
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Gualtiero Palareti, Benilde Cosmi, Cristina Legnani et al. · New England Journal of Medicine
|
25 Oct 2006 |
629 |
| 18 |
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino et al. · The Lancet Oncology
Open access |
12 Jun 2020 |
624 |
| 19 |
The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)
on behalf of the VIP1 study group et al. · Intensive Care Medicine
Open access |
21 Sep 2017 |
618 |
| 20 |
MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside
Margherita Ratti, Andrea Lampis, Michele Ghidini et al. · Targeted Oncology
Open access |
25 May 2020 |
611 |
| 21 |
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini et al. · The Lancet Oncology
|
Sep 2009 |
601 |
| 22 |
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
Guido Finazzi, Roberto Marchioli, Vincenzo Brancaccio et al. · Journal of Thrombosis and Haemostasis
Open access |
29 Apr 2005 |
590 |
| 23 |
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al. · The Lancet Haematology
Open access |
13 Aug 2020 |
555 |
| 24 |
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al. · The Lancet Oncology
|
21 Oct 2018 |
532 |
| 25 |
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Vittorio Pengo, Amelia Ruffatti, Cristina Legnani et al. · Blood
Open access |
16 Jul 2011 |
465 |
| 26 |
Broad targeting of angiogenesis for cancer prevention and therapy
Zongwei Wang et al. · Seminars in Cancer Biology
Open access |
16 Jan 2015 |
462 |
| 27 |
Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis
Enrico Ammirati et al. · Circulation
Open access |
15 May 2018 |
449 |
| 28 |
Vitamin D levels and patient outcome in chronic kidney disease
Pietro Ravani, Fabio Malberti, Giovanni Luigi Tripepi et al. · Kidney International
Open access |
8 Oct 2008 |
438 |
| 29 |
ST-Elevation Myocardial Infarction in Patients With COVID-19
Giulio Giuseppe Stefanini et al. · Circulation
Open access |
30 Apr 2020 |
432 |
| 30 |
East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
Johan M. Burisch et al. · Gut
Open access |
20 Apr 2013 |
432 |
| 31 |
Total Neoadjuvant Therapy in Rectal Cancer
Fausto Petrelli, Francesca Trevisan, Mary Cabiddu et al. · Annals of Surgery
|
18 Jul 2019 |
415 |
| 32 |
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti, Loredana Ruggeri, Alessandra D’Addio et al. · Blood
Open access |
27 Jul 2011 |
405 |
| 33 |
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Giovanni Fucà et al. · British Journal of Cancer
Open access |
18 May 2020 |
397 |
| 34 |
Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease
Pietro Ravani, Giovanni Luigi Tripepi, Fabio Malberti et al. · Journal of the American Society of Nephrology
|
8 Jun 2005 |
379 |
| 35 |
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al. · Journal of Clinical Oncology
Open access |
10 Apr 2012 |
368 |
| 36 |
Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease Severity
Lanfroi Graziani, Antonio Silvestro, Vittorio Bertone et al. · European Journal of Vascular and Endovascular Surgery
Open access |
30 Dec 2006 |
350 |
| 37 |
Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals
Giliola Calori, Guido Lattuada, Lorenzo Piemonti et al. · Diabetes Care
Open access |
11 Oct 2010 |
349 |
| 38 |
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al. · The Lancet Oncology
Open access |
9 Mar 2020 |
335 |
| 39 |
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Miranda Gogishvili et al. · Nature Medicine
Open access |
25 Aug 2022 |
318 |
| 40 |
Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection
Corrado Lettieri et al. · The American Journal of Cardiology
|
10 Apr 2015 |
310 |
| 41 |
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli, Diego Signorelli, Michele Ghidini et al. · Cancers
ReviewOpen access |
27 Feb 2020 |
304 |
| 42 |
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Keith I. Block et al. · Seminars in Cancer Biology
Open access180 authors |
18 Nov 2015 |
302 |
| 43 |
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
Manuela Milani, Tomasz Rzymski, Howard R. Mellor et al. · Cancer Research
|
5 May 2009 |
302 |
| 44 |
Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact
Chiara Foroni, Massimo Broggini, Daniele Generali et al. · Cancer Treatment Reviews
|
3 Dec 2011 |
283 |
| 45 |
Pregnancy in CKD Stages 3 to 5: Fetal and Maternal Outcomes
Enrico Imbasciati, Gina Alessandra Gregorini, Gianfranca Cabiddu et al. · American Journal of Kidney Diseases
|
30 May 2007 |
282 |
| 46 |
Fatty liver index and mortality: The cremona study in the 15th year of follow-up
Giliola Calori, Guido Lattuada, Francesca Ragogna et al. · Hepatology
Open access |
12 Apr 2011 |
261 |
| 47 |
Comparison of Microbiological, Histological, and Immunomodulatory Parameters in Response to Treatment with Either Combination Therapy with Prednisone and Metronidazole or Probiotic VSL#3 Strains in Dogs with Idiopathic Inflammatory Bowel Disease
Giacomo Rossi, G. Pengo, Marco Caldín et al. · PLoS ONE
Open access |
10 Apr 2014 |
257 |
| 48 |
Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer
Daniele Generali, Alfredo Berruti, Maria Pia Brizzi et al. · Clinical Cancer Research
Open access |
Aug 2006 |
248 |
| 49 |
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests
Enrico Baldi et al. · European Heart Journal
Open access |
3 Jun 2020 |
245 |
| 50 |
Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy
Federico Alberici et al. · Kidney International Reports
Open access |
4 Apr 2020 |
242 |